Treace Medical (TMCI) Concepts announced the successful completion of the first cases combining IntelliGuide PSI technology with the Adductoplasty System for a CT-based, patient specific correction personalized to the patient’s unique midfoot deformity. IntelliGuide PSI, incorporating RedPoint technology, is the first and only patient-specific cut guide system available for correction of bunion and/or midfoot deformities in the U.S. IntelliGuide PSI provides an AI-enabled software approach to convert a patient’s CT-scan to a pre-operative surgical plan and produce a 3D-printed cut guide specific to the patient’s deformity for efficient and personalized intra-operative guidance. It is estimated that midfoot deformities, such as metatarsus adductus, may occur in up to 30% of bunion patients. Eric Kuhlman, DPM of Center for Spine & Orthopedics in Denver, who performed an initial IntelliGuide Adductoplasty case commented, “This technology is going to revolutionize the way that I approach treating patients with bunion and related midfoot deformities. The virtual planning process helped me fully visualize the complex three-dimensional metatarsus adductus midfoot correction before stepping foot in the OR and the 3D-printed cut guides added a new level of intra-operative precision, efficiency, and confidence to the procedure. Just as PSI has advanced other areas of orthopedics, I expect IntelliGuide PSI to rapidly expand our understanding and treatment of these common, yet challenging foot deformities.”
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TMCI:
- Treace Medical announces Guy Guglielmino as chief commercial officer
- Treace Medical assumed with an Equal Weight at Morgan Stanley
- Treace Medical price target raised to $8 from $7 at Stifel
- Treace Medical Concepts Reports Strong Q3 2024 Growth
- Closing Bell Movers: Exact Sciences falls 30% after results, guidance cut
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
